Intra-Cellular Therapies Stock Price, News & Analysis (NASDAQ:ITCI) $61.46 -1.38 (-2.20%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$61.22▼$63.9350-Day Range$46.37▼$62.8452-Week Range$42.01▼$67.05Volume886,577 shsAverage Volume768,921 shsMarket Capitalization$5.91 billionP/E RatioN/ADividend YieldN/APrice Target$78.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.0% Upside$78.67 Price TargetShort InterestBearish3.54% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment1.09Based on 4 Articles This WeekInsider TradingSelling Shares$5.35 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.68) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector176th out of 952 stocksPharmaceutical Preparations Industry71st out of 434 stocks 3.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.67, Intra-Cellular Therapies has a forecasted upside of 28.0% from its current price of $61.46.Amount of Analyst CoverageIntra-Cellular Therapies has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.54% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Intra-Cellular Therapies has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 3.9 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Intra-Cellular Therapies this week, compared to 3 articles on an average week.Search Interest3 people have searched for ITCI on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,346,680.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions86.94% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -38.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -38.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 8.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesDecember 4, 2023 | americanbankingnews.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 7.9% in NovemberNovember 25, 2023 | americanbankingnews.comInvestors Purchase Large Volume of Call Options on Intra-Cellular Therapies (NASDAQ:ITCI)December 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 23, 2023 | finance.yahoo.comWall Street Analysts Think Intra-Cellular (ITCI) Could Surge 33.02%: Read This Before Placing a BetNovember 20, 2023 | seekingalpha.comThe Right Play On Intra-Cellular TherapiesNovember 15, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 15, 2023 | finance.yahoo.comInsider Sell Alert: EVP Michael Halstead Sells 50,000 Shares of Intra-Cellular Therapies Inc (ITCI)November 13, 2023 | seekingalpha.comIntra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health BlockbusterDecember 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comWall Street Analysts Believe Intra-Cellular (ITCI) Could Rally 41.19%: Here's is How to TradeNovember 6, 2023 | finance.yahoo.comWe Think Intra-Cellular Therapies (NASDAQ:ITCI) Can Easily Afford To Drive Business GrowthNovember 2, 2023 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Reports Q3 2023 Earnings, Raises Sales GuidanceNovember 2, 2023 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales GuidanceNovember 2, 2023 | finance.yahoo.comIntra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales GuidanceOctober 31, 2023 | finance.yahoo.comIntra-Cellular Therapies to Participate in Two Upcoming Investor ConferencesOctober 29, 2023 | finance.yahoo.comI'm Targeting Intra-Cellular Therapies for a Covered-Call PlayOctober 26, 2023 | finance.yahoo.comIntra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOctober 26, 2023 | finance.yahoo.comIntra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and WebcastSeptember 20, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 20, 2023 | gurufocus.comInsider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies IncSeptember 11, 2023 | benzinga.comIntra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed FeaturesSeptember 5, 2023 | finance.yahoo.comLoss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-TermSeptember 5, 2023 | finance.yahoo.comIntra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 23, 2023 | msn.comCantor Fitzgerald Reiterates Intra-Cellular Therapies (ITCI) Overweight RecommendationAugust 12, 2023 | seekingalpha.comIntra-Cellular Therapies: Caplyta's Rise And A Promising PipelineAugust 4, 2023 | finance.yahoo.comIntra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales GuidanceAugust 3, 2023 | seekingalpha.comIntra-Cellular Therapies Q2 2023 Earnings PreviewSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees561Year FoundedN/APrice Target and Rating Average Stock Price Target$78.67 High Stock Price Target$101.00 Low Stock Price Target$62.00 Potential Upside/Downside+28.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-256,260,000.00 Net Margins-36.92% Pretax Margin-36.88% Return on Equity-24.91% Return on Assets-21.34% Debt Debt-to-Equity RatioN/A Current Ratio6.81 Quick Ratio6.40 Sales & Book Value Annual Sales$250.31 million Price / Sales23.63 Cash FlowN/A Price / Cash FlowN/A Book Value$6.93 per share Price / Book8.87Miscellaneous Outstanding Shares96,240,000Free Float92,966,000Market Cap$5.91 billion OptionableOptionable Beta1.10 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 70)Co-Founder, Chairman, CEO & President Comp: $2.23MMr. Lawrence J. Hineline CPA (Age 67)Senior VP of Finance, CFO, Treasurer & Assistant Secretary Comp: $820.53kMr. Michael I. Halstead J.D. (Age 50)Executive VP, General Counsel & Secretary Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 54)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 60)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 72)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 52)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 61)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsMore ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSElanco Animal HealthNYSE:ELANAscendis Pharma A/SNASDAQ:ASNDBridgeBio PharmaNASDAQ:BBIOGrifolsNASDAQ:GRFSView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 114,370 shares on 12/1/2023Ownership: 1.887%American Century Companies Inc.Bought 21,604 shares on 11/30/2023Ownership: 0.459%Neo Ivy Capital ManagementBought 872 shares on 11/30/2023Ownership: 0.001%Deutsche Bank AGSold 41,345 shares on 11/24/2023Ownership: 0.619%Polar Capital Holdings PlcBought 600,000 shares on 11/22/2023Ownership: 1.039%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 8 Wall Street research analysts have issued 12 month price targets for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $101.00. On average, they expect the company's stock price to reach $78.67 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2023? Intra-Cellular Therapies' stock was trading at $52.92 at the start of the year. Since then, ITCI stock has increased by 16.1% and is now trading at $61.46. View the best growth stocks for 2023 here. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,410,000 shares, an increase of 7.9% from the October 31st total of 3,160,000 shares. Based on an average daily trading volume, of 833,200 shares, the days-to-cover ratio is currently 4.1 days. View Intra-Cellular Therapies' Short Interest. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.34. The biopharmaceutical company had revenue of $126.17 million for the quarter, compared to analyst estimates of $118.35 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 24.91% and a negative net margin of 36.92%. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.41%), JPMorgan Chase & Co. (2.14%), Invesco Ltd. (2.01%), Wellington Management Group LLP (1.89%), Clearbridge Investments LLC (1.46%) and Polar Capital Holdings Plc (1.04%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.